New approaches to clinical assessment of disability and cognition
Disability progression is a core element of the medical, social and economic impact of MS, and more than 80% of patients with relapsing-remitting MS (RRMS) progress to a secondary phase characterised by significant disability and cognitive decline.1 A cohort study, presented today at ECTRIMS–ACTRIMS by Omid Beiki and colleagues, brings some encouraging news for patients: among o
Login to register to read this article
If you do not have a Log in, please register to be part of a big community, experience premium content and stay informed about exclusive professional events.
Log InNot registered yet? Register now